Immune-related gene signatures predict the outcome of neoadjuvant chemotherapy

OncoImmunology

Volumn 3, Issue 2, 2014, Pages

  Stoll, Gautier ^a,b   Enot, David ^c   Mlecnik, Bernhard ^a,b,d,e   Galon, Jérôme ^a,b,d,e   Zitvogel, Laurence ^f,g,h   Kroemer, Guido ^a,b,c,h,i  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d Laboratory of Integrative Cancer Immunology   (France)

^e University Paris XI   (France)

^f UNIVERSITÉ PARIS SACLAY   (France)

^g Center of Clinical Investigations in Biotherapies of Cancer   (France)

^h INSERM   (France)

ⁱ HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Autophagy; Breast cancer; Colorectal cancer; Endoplasmic stress; Immunogenic cell death; Tumor infiltrating lymphocytes

Indexed keywords

CXCL13 CHEMOKINE; GAMMA INTERFERON;

ARTICLE; AUTOPHAGY; BIOINFORMATICS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CELL DEATH; CELLULAR IMMUNITY; COHORT ANALYSIS; DATA ANALYSIS; DRUG RESPONSE; ENDOPLASMIC RETICULUM STRESS; GENE IDENTIFICATION; IMMUNOGENICITY; PHARMACOGENETICS; REPRODUCIBILITY; TRANSCRIPTOMICS; TUMOR IMMUNITY;

EID: 84899083929     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.27884     Document Type: Article

References (68)

1. Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 2011; 8:151-60; PMID:21364688; http://dx.doi.org/10.1038/nrclinonc.2010.223.
2. Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 2013; 39:74-88; PMID:23890065; http://dx.doi.org/10.1016/j.immuni.2013.06.014.
3. Angell H, Galon J. From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. Curr Opin Immunol 2013; 25:261-7; PMID:23579076; http://dx.doi. org/10.1016/j.coi.2013.03.004.
4. Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12:298-306; PMID:22419253; http://dx.doi.org/10.1038/nrc3245.
5. Galon J, Angell HK, Bedognetti D, Marincola FM. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 2013; 39:11-26; PMID:23890060; http://dx.doi.org/10.1016/j.immuni.2013.07.008.
6. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960-4; PMID:17008531; http://dx.doi.org/10.1126/science.1129139.
7. Galon J, Fridman W-H, Pagès F. The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res 2007; 67:1883-6; PMID:17332313; http://dx.doi.org/10.1158/0008-5472.CAN-06-4806.
8. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 2011; 1:54-67; PMID:22039576; http://dx.doi. org/10.1158/2159-8274.CD-10-0028.
9. Mahmoud SMA, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, Ellis IO, Green AR. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 2011; 29:1949-55; PMID:21483002; http://dx.doi. org/10.1200/JCO.2010.30.5037.
10. Mahmoud S, Lee A, Ellis I, Green A. CD8(+) T lymphocytes infiltrating breast cancer: A promising new prognostic marker? Oncoimmunology 2012; 1:364-5; PMID:22737616; http://dx.doi.org/10.4161/onci.18614.
11. Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL, Banham AH. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006; 24:5373-80; PMID:17135638; http://dx.doi.org/10.1200/JCO.2006.05.9584.
12. Gobert M, Treilleux I, Bendriss-Vermare N, Bachelot T, Goddard-Leon S, Arfi V, Biota C, Doffin AC, Durand I, Olive D, et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res 2009; 69:2000-9; PMID:19244125; http://dx.doi.org/10.1158/0008-5472.CAN-08-2360.
13. Denkert C, Loibl S, Noske A, Roller M, Müller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R, Hanusch C, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010; 28:105-13; PMID:19917869; http://dx.doi. org/10.1200/JCO.2009.23.7370.
14. Loi S. Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy. Oncoimmunology 2013; 2:e24720; PMID:24073365; http://dx.doi. org/10.4161/onci.24720.
15. Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, Rouas G, Francis P, Crown JP, Hitre E, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 2013; 31:860-7; PMID:23341518; http://dx.doi.org/10.1200/JCO.2011.41.0902.
16. West NR, Milne K, Truong PT, Macpherson N, Nelson BH, Watson PH. Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res 2011; 13:R126; PMID:22151962; http://dx.doi.org/10.1186/bcr3072.
17. Ladoire S, Mignot G, Dabakuyo S, Arnould L, Apetoh L, Rébé C, Coudert B, Martin F, Bizollon MH, Vanoli A, et al. In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival. J Pathol 2011; 224:389-400; PMID:21437909; http://dx.doi.org/10.1002/path.2866.
18. Senovilla L, Vitale I, Martins I, Tailler M, Pailleret C, Michaud M, Galluzzi L, Adjemian S, Kepp O, Niso-Santano M, et al. An immunosurveillance mechanism controls cancer cell ploidy. Science 2012; 337:1678-84; PMID:23019653; http://dx.doi. org/10.1126/science.1224922.
19. Ascierto ML, Kmieciak M, Idowu MO, Manjili R, Zhao Y, Grimes M, Dumur C, Wang E, Ramakrishnan V, Wang XY, et al. A signature of immune function genes associated with recurrencefree survival in breast cancer patients. Breast Cancer Res Treat 2012; 131:871-80; PMID:21479927; http://dx.doi.org/10.1007/s10549-011-1470-x.
20. Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G, Delorenzi M, Piccart M, Sotiriou C. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 2008; 14:5158-65; PMID:18698033; http://dx.doi.org/10.1158/1078-0432.CCR-07-4756.
21. Ignatiadis M, Singhal SK, Desmedt C, Haibe-Kains B, Criscitiello C, Andre F, Loi S, Piccart M, Michiels S, Sotiriou C. Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. J Clin Oncol 2012; 30:1996-2004; PMID:22508827; http://dx.doi.org/10.1200/JCO.2011.39.5624.
22. Yau C, Esserman L, Moore DH, Waldman F, Sninsky J, Benz CC. A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer. Breast Cancer Res 2010; 12:R85; PMID:20946665; http://dx.doi. org/10.1186/bcr2753.
23. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31:51-72; PMID:23157435; http://dx.doi.org/10.1146/annurev-immunol-032712-100008.
24. Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P, Shen S, Kepp O, Scoazec M, Mignot G, et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011; 334:1573-7; PMID:22174255; http://dx.doi.org/10.1126/science.1208347.
25. Panaretakis T, Kepp O, Brockmeier U, Tesniere A, Bjorklund AC, Chapman DC, Durchschlag M, Joza N, Pierron G, van Endert P, et al. Mechanisms of preapoptotic calreticulin exposure in immunogenic cell death. EMBO J 2009; 28:578-90; PMID:19165151; http://dx.doi.org/10.1038/emboj.2009.1.
26. Ma Y, Galluzzi L, Zitvogel L, Kroemer G. Autophagy and cellular immune responses. Immunity 2013; 39:211-27; PMID:23973220; http://dx.doi. org/10.1016/j.immuni.2013.07.017.
27. Martins I, Wang Y, Michaud M, Ma Y, Sukkurwala AQ, Shen S, Kepp O, Métivier D, Galluzzi L, Perfettini JL, et al. Molecular mechanisms of ATP secretion during immunogenic cell death. Cell Death Differ 2014; 21:79-91; PMID:23852373; http://dx.doi. org/10.1038/cdd.2013.75.
28. Wang Y, Wang XN. Cell-in-cell: A virgin land of cell biology. Oncoimmunology 2013; 2:e25988; PMID:24244895; http://dx.doi.org/10.4161/onci.25988.
29. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13:54-61; PMID:17187072; http://dx.doi.org/10.1038/nm1523.
30. Menger L, Vacchelli E, Adjemian S, Martins I, Ma Y, Shen S, Yamazaki T, Sukkurwala AQ, Michaud M, Mignot G, et al. Cardiac glycosides exert anticancer effects by inducing immunogenic cell death. Sci Transl Med 2012; 4:143ra99; PMID:22814852; http://dx.doi.org/10.1126/scitranslmed.3003807.
31. Bonnefoi H, Potti A, Delorenzi M, Mauriac L, Campone M, Tubiana-Hulin M, Petit T, Rouanet P, Jassem J, Blot E, et al. Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol 2007; 8:1071-8; PMID:18024211; http://dx.doi. org/10.1016/S1470-2045(07)70345-5.
32. Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, et al. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA 2011; 305:1873-81; PMID:21558518; http://dx.doi.org/10.1001/jama.2011.593.
33. Tabchy A, Valero V, Vidaurre T, Lluch A, Gomez H, Martin M, Qi Y, Barajas-Figueroa LJ, Souchon E, Coutant C, et al. Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin Cancer Res 2010; 16:5351-61; PMID:20829329; http://dx.doi. org/10.1158/1078-0432.CCR-10-1265.
34. Lesokhin AM, Merghoub T, Wolchok JD. Myeloidderived suppressor sells and the efficacy of CD8(+) T-cell immunotherapy. Oncoimmunology 2013; 2:e22764; PMID:23525353; http://dx.doi. org/10.4161/onci.22764.
35. Ming Lim C, Stephenson R, Salazar AM, Ferris RL. TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR(+) head and neck cancer cells. Oncoimmunology 2013; 2:e24677; PMID:23894722; http://dx.doi.org/10.4161/onci.24677.
36. Demaria S, Pilones KA, Formenti SC, Dustin ML. Exploiting the stress response to radiation to sensitize poorly immunogenic tumors to anti-CTLA-4 treatment. Oncoimmunology 2013; 2:e23127; PMID:23802063; http://dx.doi.org/10.4161/onci.23127.
37. Trapani JA, Thia KY, Andrews M, Davis ID, Gedye C, Parente P, Svobodova S, Chia J, Browne K, Campbell IG, et al. Human perforin mutations and susceptibility to multiple primary cancers. Oncoimmunology 2013; 2:e24185; PMID:23734337; http://dx.doi. org/10.4161/onci.24185.
38. Vacca P, Martini S, Mingari MC, Moretta L. NK cells from malignant pleural effusions are potent antitumor effectors: A clue for adoptive immunotherapy? Oncoimmunology 2013; 2:e23638; PMID:23734317; http://dx.doi.org/10.4161/onci.23638.
39. Lorvik KB, Haabeth OAW, Clancy T, Bogen B, Corthay A. Molecular profiling of tumor-specific TH1 cells activated in vivo. Oncoimmunology 2013; 2:e24383; PMID:23762808; http://dx.doi. org/10.4161/onci.24383.
40. Lindenberg JJ, van de Ven R, Lougheed SM, Zomer A, Santegoets SJ, Griffioen AW, Hooijberg E, van den Eertwegh AJ, Thijssen VL, Scheper RJ, et al. Functional characterization of a STAT3-dependent dendritic cell-derived CD14(+) cell population arising upon IL-10-driven maturation. Oncoimmunology 2013; 2:e23837; PMID:23734330; http://dx.doi. org/10.4161/onci.23837.
41. Sung W-W, Lee H. The role of interleukin-10 in the progression of human papillomavirus-associated lung carcinoma. Oncoimmunology 2013; 2:e25854; PMID:24244909; http://dx.doi.org/10.4161/onci.25854.
42. Velasco-Velázquez M, Pestell RG. The CCL5/CCR5 axis promotes metastasis in basal breast cancer. Oncoimmunology 2013; 2:e23660; PMID:23734321; http://dx.doi.org/10.4161/onci.23660.
43. Li M, Knight DA, A Snyder L, Smyth MJ, Stewart TJ. A role for CCL2 in both tumor progression and immunosurveillance. Oncoimmunology 2013; 2:e25474; PMID:24073384; http://dx.doi. org/10.4161/onci.25474.
44. Wong JL, Muthuswamy R, Bartlett DL, Kalinski P. IL-18-based combinatorial adjuvants promote the intranodal production of CCL19 by NK cells and dendritic cells of cancer patients. Oncoimmunology 2013; 2:e26245; PMID:24228233; http://dx.doi. org/10.4161/onci.26245.
45. Guirnalda P, Wood L, Goenka R, Crespo J, Paterson Y. Interferon γ-induced intratumoral expression of CXCL9 alters the local distribution of T cells following immunotherapy with Listeria monocytogenes. Oncoimmunology 2013; 2:e25752; PMID:24083082; http://dx.doi.org/10.4161/onci.25752.
46. Kennedy BP, Diehl RE, Boie Y, Adam M, Dixon RA. Gene characterization and promoter analysis of the human 5-lipoxygenase-activating protein (FLAP). J Biol Chem 1991; 266:8511-6; PMID:1673682.
47. Wang J, Wu X, Simonavicius N, Tian H, Ling L. Medium-chain fatty acids as ligands for orphan G protein-coupled receptor GPR84. J Biol Chem 2006; 281:34457-64; PMID:16966319; http://dx.doi. org/10.1074/jbc.M608019200.
48. Karthaus N, Torensma R, Tel J. Deciphering the message broadcast by tumor-infiltrating dendritic cells. Am J Pathol 2012; 181:733-42; PMID:22796439; http://dx.doi.org/10.1016/j.ajpath.2012.05.012.
49. Kim R, Emi M, Tanabe K, Murakami S. Role of the unfolded protein response in cell death. Apoptosis 2006; 11:5-13; PMID:16374548; http://dx.doi. org/10.1007/s10495-005-3088-0.
50. Settembre C, Fraldi A, Medina DL, Ballabio A. Signals from the lysosome: a control centre for cellular clearance and energy metabolism. Nat Rev Mol Cell Biol 2013; 14:283-96; PMID:23609508; http://dx.doi.org/10.1038/nrm3565.
51. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331:1565-70; PMID:21436444; http://dx.doi.org/10.1126/science.1203486.
52. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011; 29:235-71; PMID:21219185; http://dx.doi.org/10.1146/annurev-immunol-031210-101324.
53. Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, Angell H, Fredriksen T, Lafontaine L, Berger A, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 2013; 39:782-95; PMID:24138885; http://dx.doi.org/10.1016/j. immuni.2013.10.003.
54. Mlecnik B, Tosolini M, Charoentong P, Kirilovsky A, Bindea G, Berger A, Camus M, Gillard M, Bruneval P, Fridman WH, et al. Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology 2010; 138:1429-40; PMID:19909745; http://dx.doi. org/10.1053/j.gastro.2009.10.057.
55. Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, Bruneval P, Trajanoski Z, Fridman WH, Pagès F, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 2011; 29:610-8; PMID:21245428; http://dx.doi.org/10.1200/JCO.2010.30.5425.
56. Harding HP, Zhang Y, Zeng H, Novoa I, Lu PD, Calfon M, Sadri N, Yun C, Popko B, Paules R, et al. An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol Cell 2003; 11:619-33; PMID:12667446; http://dx.doi.org/10.1016/S1097-2765(03)00105-9.
57. Kroemer G, Mariño G, Levine B. Autophagy and the integrated stress response. Mol Cell 2010; 40:280-93; PMID:20965422; http://dx.doi.org/10.1016/j. molcel.2010.09.023.
58. Ladoire S, Chaba K, Martins I, Sukkurwala AQ, Adjemian S, Michaud M, Poirier-Colame V, Andreiuolo F, Galluzzi L, White E, et al. Immunohistochemical detection of cytoplasmic LC3 puncta in human cancer specimens. Autophagy 2012; 8:1175-84; PMID:22647537; http://dx.doi. org/10.4161/auto.20353.
59. Smith JJ, Deane NG, Wu F, Merchant NB, Zhang B, Jiang A, Lu P, Johnson JC, Schmidt C, Bailey CE, et al. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology 2010; 138:958-68; PMID:19914252; http://dx.doi.org/10.1053/j. gastro.2009.11.005.
60. Freeman TJ, Smith JJ, Chen X, Washington MK, Roland JT, Means AL, Eschrich SA, Yeatman TJ, Deane NG, Beauchamp RD. Smad4-mediated signaling inhibits intestinal neoplasia by inhibiting expression of β-catenin. Gastroenterology 2012; 142:562, e2; PMID:22115830; http://dx.doi.org/10.1053/j. gastro.2011.11.026.
61. Gröne J, Lenze D, Jurinovic V, Hummel M, Seidel H, Leder G, Beckmann G, Sommer A, Grützmann R, Pilarsky C, et al. Molecular profiles and clinical outcome of stage UICC II colon cancer patients. Int J Colorectal Dis 2011; 26:847-58; PMID:21465190; http://dx.doi.org/10.1007/s00384-011-1176-x.
62. Rickman DS, Millon R, De Reynies A, Thomas E, Wasylyk C, Muller D, Abecassis J, Wasylyk B. Prediction of future metastasis and molecular characterization of head and neck squamous-cell carcinoma based on transcriptome and genome analysis by microarrays. Oncogene 2008; 27:6607-22; PMID:18679425; http://dx.doi.org/10.1038/onc.2008.251.
63. Li Q, Birkbak NJ, Gyorffy B, Szallasi Z, Eklund AC. Jetset: selecting the optimal microarray probe set to represent a gene. BMC Bioinformatics 2011; 12:474; PMID:22172014; http://dx.doi. org/10.1186/1471-2105-12-474.
64. R Core Team. R: A language and environment for statistical computing. (2013). at .
65. Dombroski BA, Nayak RR, Ewens KG, Ankener W, Cheung VG, Spielman RS. Gene expression and genetic variation in response to endoplasmic reticulum stress in human cells. Am J Hum Genet 2010; 86:719-29; PMID:20398888; http://dx.doi. org/10.1016/j.ajhg.2010.03.017.
66. Pietrocola F, Izzo V, Niso-Santano M, Vacchelli E, Galluzzi L, Maiuri MC, Kroemer G. Regulation of autophagy by stress-responsive transcription factors. Semin Cancer Biol 2013; 23:310-22; PMID:23726895; http://dx.doi.org/10.1016/j. semcancer.2013.05.008.
67. Palmieri M, Impey S, Kang H, di Ronza A, Pelz C, Sardiello M, Ballabio A. Characterization of the CLEAR network reveals an integrated control of cellular clearance pathways. Hum Mol Genet 2011; 20:3852-66; PMID:21752829; http://dx.doi. org/10.1093/hmg/ddr306.
68. Huang E, Cheng SH, Dressman H, Pittman J, Tsou MH, Horng CF, Bild A, Iversen ES, Liao M, Chen CM, et al. Gene expression predictors of breast cancer outcomes. Lancet 2003; 361:1590-6; PMID:12747878; http://dx.doi.org/10.1016/S0140-6736(03)13308-9.